SECURITIES AND EXCHANGE COMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 10, 2003
NOVAVAX, INC.
-------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-26770 22-2816046
-------- ------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File No.) Identification No.)
8320 GUILFORD ROAD, COLUMBIA, MD 21046
-------------------------------- -----
(Address of principal executive offices) (Zip code)
(301) 854-3900
--------------
Registrant's telephone number, including area code
NOT APPLICABLE
--------------
(Former name or former address, if changed since last report)
NOVAVAX, INC.
ITEMS TO BE INCLUDED IN THIS REPORT
ITEM 7. EXHIBITS.
99.1 Press Release dated November 10, 2003.
ITEM 12.RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On November 10, 2003, Novavax, Inc. reported its third quarter earnings
for 2003.
A copy of the Press Release is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NOVAVAX, INC.
Date: November 10, 2003 By: /s/ Dennis W. Genge
------------------------------------------------
Dennis W. Genge, Vice President and Chief
Financial Officer/Treasurer
3